Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS‑CoV‑2 3CL Protease Inhibitor

• Takayuki Katsube,
• Safwan Kezbor,
• Ryosuke Shimizu,
• Ryuji Kubota

Affiliations

Takayuki Katsube

Clinical Pharmacology and Pharmacokinetics, Shionogi & Co., Ltd.

Safwan Kezbor

Shionogi Inc.

Ryosuke Shimizu

Clinical Pharmacology and Pharmacokinetics, Shionogi & Co., Ltd.

Ryuji Kubota

Clinical Pharmacology and Pharmacokinetics, Shionogi & Co., Ltd.